• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Initial Public Offering (IPO)

This CEO is swallowing his own devices to fund his swimming PillBot

March 14, 2022 By Jim Hammerand

As he prepared to swallow his robot for the first time, Torrey Smith’s doctors warned that the battery was his greatest threat. If the capsule came apart and the battery burned the tissue lining his stomach, it would only be the beginning of a very bad experience. “I was just hoping that we would get […]

Filed Under: 510(k), Blog, Business/Financial News, Catheters, Diagnostics, Endoscopic, Featured, Food & Drug Administration (FDA), Imaging, Initial Public Offering (IPO), News Well, Oncology, Optical/Ophthalmic, Regulatory/Compliance, Research & Development, Robotics Tagged With: Endiatx, Google, Mayo Clinic, Medtronic, Rani Therapeutics

BD board approves Embecta diabetes business spinoff

February 1, 2022 By Sean Whooley

BD (NYSE:BDX) announced today that its board of directors approved the planned spinoff of its diabetes care business, Embecta. Franklin Lakes, N.J.-based BD confirmed in May 2021 that it planned to spin off its diabetes care business as an independent, publicly-traded company during the first half of 2022, and in December 2021, it confirmed the […]

Filed Under: Business/Financial News, Diabetes, Drug Pumps, Drug-Device Combinations, Featured, Initial Public Offering (IPO), Wall Street Beat Tagged With: BD, embecta

Pear Therapeutics closes SPAC merger, lists on Nasdaq

December 6, 2021 By Sean Whooley

Pear Therapeutics today began trading on the Nasdaq market following the completion of a previously announced merger at the end of last week. Boston-based Pear confirmed in June that it would go public by merging Thimble Point Acquisition Corp., a special purpose acquisition company (SPAC). Following approval from Thimble Point’s stockholders at the end of […]

Filed Under: Business/Financial News, Digital Health, Featured, Funding Roundup, Health Technology, Initial Public Offering (IPO), MassDevice Earnings Roundup, Software / IT, Wall Street Beat Tagged With: Pear Therapeutics

Pear Therapeutics picks up another $50M ahead of going public through SPAC merger

November 15, 2021 By Sean Whooley

Pear Therapeutics and Thimble Point Acquisition Corp. announced today that they received additional funding worth $50 million ahead of a merger. Boston-based Pear Therapeutics confirmed in June that it will go public by merging Thimble Point Acquisition Corp., a special purpose acquisition company (SPAC). A special meeting will be held for Thimble Point stockholders to […]

Filed Under: Business/Financial News, Digital Health, Featured, Funding Roundup, Health Technology, Initial Public Offering (IPO), Mergers & Acquisitions, Neurological, Patient Monitoring, Software / IT, Wall Street Beat Tagged With: Pear Therapeutics, Thimble Point Acquisition Corp.

LumiraDx goes public as SPAC deal closes

September 29, 2021 By Chris Newmarker

LumiraDx shares are trading at more than $8 apiece on the Nasdaq today under the symbol LMDX after the company completed its merger with a SPAC called CA Healthcare Acquisition Corp. The point of care diagnostic testing company has a pipeline of more than 30 assays across common health conditions, including infectious diseases, cardiovascular diseases, […]

Filed Under: Business/Financial News, Diagnostics, Digital Health, Featured, Funding Roundup, Initial Public Offering (IPO), Wall Street Beat Tagged With: LumiraDX, SPAC, SPACs

Pavmed subsidiary Lucid Diagnostics files registration statement for IPO

September 23, 2021 By Sean Whooley

Pavmed (NSDQ:PAVM) subsidiary Lucid Diagnostics announced that Lucid publicly filed a registration statement related to a proposed initial public offering (IPO). The number of shares of common stock and the price range for the offering have not yet been determined, according to a news release. Lucid Diagnostics intends to list its common stock on the Nasdaq market […]

Filed Under: Business/Financial News, Diagnostics, Endoscopic, Featured, Funding Roundup, Initial Public Offering (IPO), Otolaryngology/Ear, Nose & Throat (ENT), Wall Street Beat Tagged With: Lucid Diagnostics, Pavmed

Vicarious Surgical stock continues to rise

September 21, 2021 By Chris Newmarker

It’s so far, so good for Vicarious Surgical (NYSE:RBOT) during its first week of trading as a public company. The robotic surgery company’s shares were up more than 19% to $15.05 by midday today. During the company’s first day of trading yesterday, shares rose 2% to $12.60 apiece, even as the Dow Jones Industrial Average […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Initial Public Offering (IPO), Robotics, Surgical, Wall Street Beat Tagged With: SPACs, Vicarious Surgical

Stevanato Group brings in upsized IPO worth $453.5M

August 17, 2021 By Sean Whooley

Stevanato Group announced today that the underwriters of its recently completed initial public offering purchased more than 1 million additional shares. The option exercised by the underwriters saw the acquisition of an additional 1,018,280 ordinary Stevanato Group shares at $21 per share. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Business/Financial News, Drug Pumps, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Pharmaceutical, Wall Street Beat Tagged With: initial public offering, IPO, stevanato group

Memic Innovative Surgery to go public via SPAC merger

August 13, 2021 By Sean Whooley

Memic Innovative Surgery announced that it entered into a merger agreement with special purpose acquisition company MedTech Acquisition Corp. Tel Aviv, Israel-based Memic will operate under its current name upon the closing of the transaction, with Dr. Maurice R. Ferré — an independent director of MedTech and current chairman of Memic — will serve as […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Gynecological, Initial Public Offering (IPO), Mergers & Acquisitions, Robotics, Surgical, Wall Street Beat, Women's Health Tagged With: Dr. Maurice R. Ferré, MedTech Acquisition Corp., Memic Innovative Surgery, SPACs

MedTech 100 roundup: Industry climbs with earnings season in full swing

August 2, 2021 By Sean Whooley

Better-than-expected quarterly earnings are providing a further boost to medtech industry stocks. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (July 30) at 118.86 points. Two weeks ago aside — when the index shot up to 145.88 points and quickly tumbled down — this mark […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Initial Public Offering (IPO), MassDevice Earnings Roundup, Mergers & Acquisitions, Wall Street Beat Tagged With: 3m, Baxter, BD, Boston Scientific, coronavirus, COVID-19, Dexcom, Edwards Lifesciences, GE Healthcare, Hillrom, Hologic, MedTech 100 Index, Pfizer, Philips, Smith+Nephew, Stryker, Tenaya Therapeutics

Tenaya Therapeutics prices $180M IPO for targeted therapies

July 30, 2021 By Sean Whooley

Tenaya Therapeutics announced that it priced an underwritten, upsized initial public offering of common stock worth $180 million. South San Francisco–based Tenaya develops therapies for rare generic disorders and more prevalent heart conditions through gene therapy, cellular regeneration and precision medicine. The company is actively exploring different routes of administration and different infusion- and injection-based methods […]

Filed Under: Business/Financial News, Cardiovascular, Drug Pumps, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Regenerative Medicine, Wall Street Beat Tagged With: Tenaya Therapeutics

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 38
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS